Sciegen Pharmaceuticals Inc
FDA Regulatory Profile
Summary
- Total Recalls
- 7
- 510(k) Clearances
- 0
- Inspections
- 13
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|
| D-0354-2023 | Class III | Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuti | February 17, 2023 |
| D-0268-2019 | Class II | Westminister Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 69367-120-01), (b) 90-count b | October 29, 2018 |
| D-0267-2019 | Class II | Westminister Irbesartan Tablets, USP, 75 mg (a) 30-count bottle (NDC 69367-119-01), (b) 90-count bot | October 29, 2018 |
| D-0271-2019 | Class II | GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle (N | October 29, 2018 |
| D-0272-2019 | Class II | GSMS Irbesartan Tablets, USP, 300 mg,(a) 30-count bottle (NDC 60429-642-30), (b) 90-count bottle (ND | October 29, 2018 |
| D-0269-2019 | Class II | Westminister Irbesartan Tablets, USP, 300mg, Rx Only,(a) 30-count bottle (NDC 69367-121-01, (b) 90-c | October 29, 2018 |
| D-0270-2019 | Class II | GSMS Irbesartan Tablets, USP, 75 mg, 30-count bottle, Rx Only, Manufactured by ScieGen Pharmaceutica | October 29, 2018 |